Helixmith Participates in 'JP Morgan Healthcare Conference 2022'

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 6th that it will participate in the 'JP Morgan Healthcare Conference 2022' held from the 10th to the 13th. At this event, Helixmith plans to conduct partnering meetings with major global big pharma companies to discuss the possibilities of joint research and technology transfer.

The JP Morgan Healthcare Conference, held annually since 1983, is the world's largest pharmaceutical and biotech event. It gathers global major pharmaceutical companies, biotech ventures, and investment experts to share new drug research and development (R&D) achievements and status, and to discuss technology cooperation and technology transfer. Marking its 40th anniversary this year, the event will be held online again this year due to the impact of COVID-19.

Helixmith will introduce its platform technology and know-how in the gene therapy field, the excellence of 'Engensis (VM202)', the latest clinical development status, and future clinical development strategies. Along with this, it will engage in related discussions such as joint research and technology transfer with global big pharma companies.

Helixmith's gene therapy Engensis (VM202) was selected as a 'notable clinical result in Q1 2021' by Nature Biotechnology for its Phase 3-1 trial on diabetic peripheral neuropathy (DPN) last year. Ongoing clinical trials include the follow-up DPN Phase 3-2 trial in the US, amyotrophic lateral sclerosis (ALS) Phase 2a trials in the US and Korea, and Charcot-Marie-Tooth disease (CMT) Phase 1/2a trial in Korea, all progressing smoothly.

Kim Sunyoung, CEO of Helixmith, stated, “Through this JP Morgan Healthcare Conference, we plan to actively engage in discussions on joint development such as technology transfer and clinical development cooperation with multinational pharmaceutical companies.” She added, “Numerous partnering meetings with big pharma companies are already scheduled, and we expect to achieve meaningful results.”

This content was produced with the assistance of AI translation services.